Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XanADu Phase II Xanamem Trial in Mild Dementia Due to Probable Alzheimer's Disease
2016-001049-24Phase 2Completed
- Sponsor
- Actinogen Medical Limited
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of emestedastat in Alzheimer's disease (AD), sponsored by Actinogen Medical Limited. Started Dec 2016; status: completed.
02
Drugs
emestedastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-001049-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001049-24.